Ignyta, Inc. is catalyzing personalized medicine with "Rx/Dx" solutions for cancer. Our goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. We achieve this goal by leveraging our proprietary cancer genomic and epigenomic knowledge bases to discover novel targets and deliver the next generation of targeted therapeutics accompanied by highly informative biomarkers for patient selection, treatment, and monitoring.
Find out more
    Technology Platform
    Our proprietary platform uses next generation genomic, epigenomic, and other molecular technologies to elucidate biomarkers and drug targets
    Find out More
    Leading Oncology Precision Medicines
    Two leading tyrosine kinase inhibitors directed to the TrkA molecular target, among other oncogenic drivers
    Find out More
Our Vision, Mission and Values
More News